Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation - Archive ouverte HAL Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2022

Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation

(1, 2) , (1) , (3) , (3) , (3) , (2) , (1) , (2, 4, 5) , (1) , (2, 5)
1
2
3
4
5

Abstract

Bladder cancer is a common cancer; it is the tenth most common cancer in the world. Around one fourth of all diagnosed patients have muscle-invasive bladder cancer (MIBC), characterized by advanced tumors and which remains a lethal disease. The standard treatment for MIBC is the bladder removal by surgery. However, bladder-preserving alternatives are emerging by combining chemotherapy, radiotherapy and minimal surgery, aiming to increase the patient’s quality of life. The aim of the study was to improve these treatments by investigating a novel approach where in addition to radiotherapy, a receptor, TYRO3, a member of TAM receptor tyrosine kinase family known to be highly expressed on the bladder cancer cells and involved in the control of cell survival is targeted. For this, we evaluated the influence of TYRO3 expression levels on a colony or cell survival assays, DNA damage, γH2AX foci formation, gene expression profiling and cell cycle regulation, after radiation on different bladder cell models. We found that TYRO3 expression impacts the radiation response via the cell cycle dysregulation with noeffets on the DNA repair. Therefore, targeting TYRO3 is a promising sensitization marker that could be clinically employed in future treatments.
Fichier principal
Vignette du fichier
TYRO3radiation-Silina2021-IJSMpdf.pdf (3.46 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03853939 , version 1 (16-11-2022)

Identifiers

Cite

Linda Silina, Florent Dufour, Audrey Rapinat, Cécile Reyes, David Gentien, et al.. Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation. International Journal of Molecular Sciences, 2022, 23 (15), pp.8671. ⟨10.3390/ijms23158671⟩. ⟨hal-03853939⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More